Famed for his work on black holes and cosmology, he also survived decades with amyotrophic lateral sclerosis.

The gene-editing tool was effective in disabling a defective gene responsible for some forms of amyotrophic lateral sclerosis. 

By stifling autophagy in the motor neurons of a mouse model of amyotrophic lateral sclerosis (ALS), scientists stem later-stage disease progression.

Amyotrophic lateral sclerosis patients in the U.S. now have an option besides riluzole, which was approved by the FDA more than two decades ago and only extends life by two or three months.

Researchers identify a new ALS-associated gene thanks to funds generated by the social media challenge that went viral in summer 2014.

At first blush, do-it-yourself clinical trials seem pointless and reckless. But a deeper truth pervades the research and the patients who drive it forward.

Researchers uncover evidence that a retrovirus embedded within the human genome may play a role in the pathology of amyotrophic lateral sclerosis. 

A year after the viral ALS awareness campaign raised millions, researchers say they have something to show for the influx of funds.

In the midst of a debate about an experimental drug’s early approval, the US Food and Drug Administration requests that full trial results be released.

Statisticians who normally crunch numbers to forecast trends in the food-service industry turn their attention to bettering treatment of ALS.